 |
Previous Article | Next Article 
Volume 16, Number 11,
Issue of June 1, 1996
pp. 3727-3736
Copyright ©1996 Society for Neuroscience
Dopamine Receptor Agonists Regulate Levels of the Serotonin
5-HT2A Receptor and its mRNA in a Subpopulation of Rat
Striatal Neurons
Nathalie Laprade1,
Fatiha Radja2,
Tomás A. Reader2, 3, and
Jean-Jacques Soghomonian1
1 Centre de Recherche en Neurobiologie and
Département d'Anatomie, Faculté de Médecine,
Université Laval, Québec, Canada, and Départements de
2 Physiologie et 3 Psychiatrie, Faculté
de Médecine, Université de Montréal,
Québec, Canada
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES
ABSTRACT
The effects of dopamine receptor agonists on the levels of the
striatal serotonin 5-HT2A receptor and its mRNA
were investigated in rats lesioned with 6-OHDA as neonates. The mRNA
encoding for the 5-HT2A receptor was detected by
in situ hybridization histochemistry and the binding to
5-HT2A receptors was revealed with
[125I](2,5-dimethoxy-4-iodophenyl)2-aminopropane
([125I]DOI). In adult control unlesioned rats, labeling
with the 5-HT2A cRNA probe and with
[125I]DOI was concentrated in medial sectors of
the striatum. In 6-OHDA-lesioned rats, labeling with the
5-HT2A cRNA probe or with
[125I]DOI was increased in the striatum,
particularly in its lateral subdivisions. These increases were
abolished after chronic systemic administration of the dopamine
receptor agonists apomorphine or SKF-38393. The mRNA levels encoding
for the 5-HT2A receptor were further measured in
individual striatal neurons after double-labeling of sections with a
5-HT2A and a preproenkephalin (PPE) cRNA probe.
In control unlesioned rats, 5-HT2A mRNA labeling
was distributed in PPE-labeled as well as in PPE-unlabeled striatal
neurons. In 6-OHDA-lesioned rats, increased
5-HT2A mRNA labeling was found only in
PPE-unlabeled neurons and it was abolished after apomorphine or
SKF-38393 administration. These results demonstrate that agonists of
dopamine receptors inhibit the expression of
5-HT2A receptors in a subpopulation of presumed
striato-nigral neurons. We propose that this regulation plays an
important role in the control of motor activity by dopamine and 5-HT in
the basal ganglia.
Key words:
striatum;
5-HT;
dopamine;
6-OHDA;
5-HT2A
serotonin receptor;
D1 dopamine receptor
INTRODUCTION
Dopamine and 5-HT play an important role in
several brain functions. Altered regulation of these two
neurotransmitters in the basal ganglia is associated with various
behavioral dysfunctions including motor and obsessive-compulsive
disorders (Sandyk et al., 1988). The striatum, one of the major
components of the basal ganglia, receives a dense dopaminergic input
from the substantia nigra pars compacta as well as serotoninergic
projections from the dorsal raphe nucleus. Serotoninergic and
dopaminergic systems in the striatum interact with each other, and
such interaction might play a key role in their respective modes of
action. For instance, it has been demonstrated that 5-HT facilitates
the release of dopamine in the striatum (Benloucif et al., 1993 ;
Gallaway et al., 1993; Yadid et al., 1994 ; Bonhomme et al., 1995 ) and
regulates the firing rate of dopamine neurons in the substantia nigra
(Kelland et al., 1990 ). Reciprocally, dopamine afferents are able to
facilitate the release of 5-HT in the raphe dorsalis and, at the same
time, inhibit this release in the striatum (Lee and Geyer, 1984 ;
Ferré and Artigas, 1993 ; Ferré et al., 1994 ).
An interaction between dopaminergic and serotoninergic inputs to the
striatum is also evidenced in adult rats injected with 6-OHDA as
neonates. These rats demonstrate an important decrease in the number of
dopaminergic afferents and, at the same time, an increased density of
5-HT axons in the striatum, predominantly in its rostral half
(Stachowiak et al., 1984; Berger et al., 1985 ; Snyder et al., 1986 ;
Descarries et al., 1992 ). The 5-HT hyperinnervation is paralleled by an
increase in striatal 5-HT content and reuptake (Luthman et al., 1987 ;
Molina-Holgado et al., 1993 , 1994 ). Neonatal 6-OHDA lesions also induce
an increased ligand binding to striatal serotonin
5-HT1B, 5-HT1nonAB, and
5-HT2A receptors (Radja et al., 1993 ) and an
increased responsiveness of striatal neurons to iontophoretic
application of 5-HT receptor agonists (El Mansari et al., 1994 ). An
increase in 5-HT2A, but not 5-HT1A or
5-HT1C (also called 5-HT2C), mRNA
levels has also been recently reported in the striatum of rats injected
with 6-OHDA as adults (Numan et al., 1995 ).
Adult rats lesioned with 6-OHDA as neonates demonstrate supersensitive
behavioral responses to the administration of dopamine D1 receptor
agonists (Breese et al., 1985a ,b). In addition, the motor hyperactivity
exhibited by these rats under drug-free conditions has been shown to
involve 5-HT2A receptors (Luthman et al., 1991 ).
These data indicate that both the D1 and 5-HT2A
receptor subtypes are preferentially involved in some of the motor
abnormalities and adaptive changes exhibited by rats lesioned with
6-OHDA as neonates. In the present study, we tested the hypothesis that
dopamine receptor agonists, particularly D1 agonists, are involved in
the modulation of striatal 5-HT2A receptor levels
in adult rats lesioned with 6-OHDA as neonates. Because striatal
projection neurons can be distinguished as two subpopulations that
either express or do not express the preproenkephalin (PPE) mRNA, we
further analyzed the fate of the mRNA encoding for the
5-HT2A receptor in these two neuronal
subpopulations.
MATERIALS AND METHODS
Neonatal 6-OHDA treatments. Three pregnant female
Sprague-Dawley rats (Charles River, Montreal) were housed individually
with water and dry food available ad libitum. Three days
after delivery, each litter was reduced to 12 pups. Twenty-five pups
were given bilateral cerebroventricular injections of the neurotoxin
6-OHDA (Sigma, St. Louis, MO) and 6 pups (sham-operated) were injected
with the vehicle (0.9% sodium chloride and 1% ascorbic acid) under
anesthesia with methoxyflurane vapors. Pups were injected either with a
total of 100 µg of 6-OHDA in 10 µl (5 µl in each ventricle) or
with 10 µl of vehicle (sham-operated). All animals were pretreated
with the noradrenaline uptake inhibitor desipramine (25 mg/kg, s.c.) 45 min before surgery, in order to protect noradrenergic neurons.
Pharmacological treatments. Sixty days after the surgery,
the sham-operated and six of the 6-OHDA-lesioned rats were injected
subcutaneously with vehicle (0.02% acetic acid in 0.9% NaCl). The
other 6-OHDA-lesioned rats were subdivided in three groups of six or
seven animals that were injected subcutaneously with the mixed dopamine
D1/D2 receptor agonist apomorphine (5 mg/kg), the preferential dopamine
D1 receptor agonist SKF-38393 (12.5 mg/kg), or SKF-38393 in combination
with the dopamine D1 receptor antagonist SCH-23390 (0.2 mg/kg). All
injections were given twice daily for 10 d. Three hours after the last
injection, all rats were killed by decapitation; their brains were
quickly removed and kept frozen at 70°C. Tissue sections (10 or 20 µm thick) were cut at striatal level on a cryostat, thaw-mounted onto
slides coated with gelatin, and stored at 70°C until further
use.
Synthesis of the cRNA probes. Radioactive- or
digoxigenin-labeled cRNA probes were produced by in vitro
transcription from cDNA clones encoding for the rat
5-HT2A receptor (Pritchett et al., 1988 ) or the
rat PPE (Yoshikawa et al., 1984 ). The cDNAs inserted into a PSP64/65
plasmid vector were linearized with EcoRI
(5-HT2A) or SacI (PPE) restriction
enzymes. Transcription of the radioactive 5-HT2A
cRNA probe was performed using a riboprobe kit (Promega, Madison, WI)
in the presence of 2.5 µM
[35S]UTP (1000 Ci/mmol, DuPont NEN, Boston, MA)
and 10 µM unlabeled UTP. Transcription of the
digoxigenin-labeled PPE cRNA probe was performed in presence of 0.166 mM digoxigenin-UTP (Boehringer Mannheim,
Indianapolis, IN) and 0.33 mM unlabeled UTP. In
both cases, unlabeled CTP, GTP, and ATP were added in excess. The
reaction was performed for 2 hr at 37°C, and then the cDNA templates
were digested with the DNase I. The labeled cRNAs were purified by
phenol/chloroform extraction and ethanol precipitation. The length of
the cRNAs was reduced to 100-150 nucleotides by partial alkaline
hydrolysis to improve accessibility of the probe (Cox et al., 1984 ).
In situ hybridization and radioautography. Brain sections
(10 µm thick) were quickly dried at room temperature and fixed for 5 min in a solution of 3% paraformaldehyde in phosphate buffer (1 M; pH 7.2) containing 0.02% DEPC. Sections were
treated for 10 min with triethanolamine (0.1 M,
pH 8.0) containing 0.25% acetic anhydride and then for 30 min with
Tris-glycine (1 M, pH 7.0) before being
dehydrated and air dried. Each section was covered with 3-3.5 ng of
radiolabeled cRNA probe and 4 ng of the digoxigenin-labeled probe
diluted in 20 µl of hybridization solution (containing 40%
formamide, 10% dextran sulfate, 4× SSC, 10 mM
dithiothreitol, 1% sheared salmon sperm DNA, 1% yeast tRNA, 1×
Denhardt's solution containing 1% RNase-free BSA). Some control
sections were hybridized with a sense 5-HT2A or
PPE RNA probe to verify the specificity of labeling. The sections were
covered with Parafilm and placed in humidified boxes, and hybridization
was performed for 4 hr at 50°C. Posthybridization washes were in 50%
formamide (in 2× SSC) at 52°C for 5 min and 20 min, in RNase A (100 µg/ml; Sigma; in 2× SSC) for 30 min at 37°C, and in 50% formamide
(in 2× SSC) at 52°C for 5 min. Sections were further rinsed at room
temperature for 30 min in 2× SSC containing 0.05% Triton X-100 and
for 3× 5 min in Tris buffer (0.1 M, pH 7.5)
containing 0.15 M NaCl, 0.3% Triton X-100 and
2% normal sheep serum. Sections were then covered with 100 µl of an
anti-digoxigenin Fab fragment conjugated with alkaline phosphatase
(Boehringer Mannheim) diluted 1:500 in the same Tris buffer and left
overnight at 4°C. Then, the sections were rinsed for 3× 7 min in the
antibody buffer and for 2× 5 min in a Tris buffer (0.1 M; pH 9.5) containing 0.1 M
NaCl and 0.05 M MgCl. The sections were then
incubated in the dark for 2-5 hr in the same Tris buffer containing
0.24 mg/ml levamisole, 75 mg/ml nitroblue tetrazolium and 50 mg/ml
X-phosphate (all these chemicals were purchased from Boehringer
Mannheim). The reaction was stopped by dipping the slides in Tris
buffer (10 mM; pH 8.0) containing 1 mM EDTA. Sections were washed in 2× SSC for 15 min, quickly dipped in ammonium acetate (300 mM),
rinsed in 70% ethanol, and air dried. Sections were first juxtaposed
to Kodak X-OMAT-AR x-ray films for 21 d and then processed for emulsion
radioautography. In that case, sections were dipped in the Amersham
LM-1 nuclear emulsion, air dried, and stored at 4°C in light-tight
boxes in presence of desiccant. After 4-8 d of exposure, the emulsion
radioautographs were developed in Kodak D-19 for 3.5 min at 14°C and
mounted with Aquaperm mounting media (Fisher Scientific, Orangeburg,
NY).
[125I]DOI binding. The serotonin
5-HT2A receptors were labeled with
[125I]DOI (DuPont, Billerica, MA; specific activity 2200 Ci/mmol), according to Mengod's modification (Mengod et al., 1990 ;
Radja et al., 1993 ) of the protocol of McKenna et al. (1989) . Briefly,
the sections (20 µm thick) were preincubated at 25°C for 30 min in
50 mM Tris-HCl buffer (pH 7.4) containing 4 mM CaCl2, 0.1% ascorbic
acid, and 0.1% bovine serum. They were then incubated for 90 min in
the same buffer containing 200 pM
[125I]DOI, in the presence of 30 nM of unlabeled 5-HT to block
5-HT2C sites. Nonspecific binding was determined
in the presence of 4 mM cold unlabeled 5-HT.
After incubation with the radioligand, the slides were washed in cold
buffer (2× 10 min) and dried under a stream of cold air.
Autoradiographs were generated by juxtaposition of the slides to
autoradiographic film (Hyperfilm, Amersham, Arlington Heights, IL),
together with Microscales (Amersham); the exposure lasted 3 d.
[3H]mazindol binding. The density of dopamine
reuptake sites in the striatum was measured by
[3H]mazindol binding, as previously reported by
Javitch et al., (1985). Frozen sections (10 µm thick) were dried
under a flow of air and rinsed for 5 min at 4°C in 50 mM Tris buffer with 120 mM
NaCl and 5 mM KCl to wash off the endogenous
ligand. They were then incubated for 40 min in 15 nM [3H]mazindol (DuPont
NEN; specific activity, 22.7 Ci/mmol) in 50 mM
Tris buffer containing 300 mM NaCl and 5 mM KCl. Desipramine (0.3 µM) was added to the incubation medium to block
the norepinephrine transporter. Sections were then rinsed 2× 3 min in
the incubation buffer and 10 sec in distilled water and then dried
under a flow of air at room temperature. Sections were then juxtaposed
to X-OMAT-AR x-ray films (Amersham) for 14 d.
[3H]citalopram binding. The density of the
striatal 5-HT innervation was estimated after citalopram binding to
tissue sections. Fresh frozen brain sections (10 µm thick) were dried
and preincubated at room temperature for 15 min in 50 mM Tris buffer (pH 7.4; containing 120 mM NaCl and 5 mM KCl). They
were then incubated for 1 hr at room temperature in 1 nM [3H]citalopram (DuPont
NEN; specific activity, 82.0 Ci/mmol) diluted in the Tris buffer.
Nonspecific binding was determined by incubating control sections for 1 hr in the same solution containing 1 µM
imipramine. After the incubation, the sections were rinsed 2× 10 min
in ice-cold buffer and quickly dipped in ice-cold distilled water. They
were then dried under a flow of cold air and juxtaposed for 3 weeks to
tritium-sensitive films (Hyperfilms, Amersham).
Analysis of the film radioautographs. The levels of
radioautographic labeling on x-ray films were quantified in the
striatum by computerized densitometry with a Macintosh computer and an
Ultimage image analysis software (Graftek, France). The optical density
of labeling in various striatal sectors was calculated after
subtracting the optical density of the film and standardization against
emulsion-coated filters (Kodak). Internal 14C
(for 35S-labeled cRNA probe) or
125I (for 125I-labeled DOI)
standards (Amersham) were used to insure that measurements were made in
the linear portion of the film. Labeling was measured in four different
sectors in order to sample the whole striatal surface. Three sections
per animal were analyzed in each condition. The average level of
labeling was calculated for each rat and in each striatal sector
sampled. Statistically significant difference in radioautographic
labeling for each striatal sector in the different experimental groups
of rats was determined using a one-way ANOVA, whereas post-hoc paired
comparisons were performed with the PLSD Fisher's test. Statistical
significance was defined as p < 0.05.
Analysis of emulsion radioautographs. The cellular
distribution of the 5-HT2A-receptor mRNA in
striatal neurons expressing or not the PPE mRNA was examined on
emulsion radioautographs by light microscopy. First, all single or
double-labeled neurons observed in one microscopic field were mapped on
paper using a camera lucida. The mapping was performed at a
magnification of 25× and the microscopic field corresponded to an area
of 0.212 mm2. From these maps, the numbers of
neurons labeled with the 35S-radioactive
5-HT2A cRNA probe alone or with the
digoxigenin-labeled PPE cRNA probe were then calculated. In order to
provide an estimate of the ratio of labeled versus unlabeled neurons in
each microscopic field, Nissl-stained neurons on adjacent sections were
similarly mapped. The levels of mRNA encoding for the
5-HT2A receptor in individual neurons expressing
or not the PPE mRNA was then measured on emulsion radioautographs under
dark-field (for PPE-labeled neurons) or bright-field (for PPE-unlabeled
neurons) illumination at 40× magnification. The area covered by silver
grains in each neuron was measured by computerized image analysis
(National Institutes of Health IMAGE 1.55) and expressed as a number of
pixels per neuron. The number of pixels in each neuron was determined
in an area of constant dimension that was large enough to encircle the
larger neuronal profiles. A sample of ~50 neurons labeled for PPE and
50 neurons unlabeled for PPE mRNA was thus analyzed for each rat. The
average level of labeling from six rats in each experimental group was
then calculated. Statistically significant differences in labeling for
each striatal sector between the experimental groups of rats were
calculated with an ANOVA. Post hoc pairwise comparisons of
5-HT2A mRNA labeling between experimental groups
was performed for each striatal sector with a Fisher's test with
p < 0.05 considered significant.
RESULTS
Regional and cellular distribution of the 5-HT2A
receptor and its mRNA in control rats
Labeling with the 5-HT2A cRNA probe or with
[125I]DOI exhibited a latero-medial gradient of
distribution in the striatum of control rats (Fig.
1A,B). Quantitative analysis of the film
radioautographs demonstrated that the labeling with the
5-HT2A cRNA probe was higher (+33% on average)
in the medial than in the lateral sectors of the striatum (0.048 ± 0.002 vs 0.032 ± 0.002; n = 6). Similarly, the level of
[125I]DOI binding was higher (+43% on average)
in the medial than in the lateral striatal sectors (0.136 ± 0.023 vs
0.078 ± 0.012; n = 6).
Fig. 1.
Negative images of x-ray films from frontal brain
sections processed for in situ hybridization with a
35S-labeled 5-HT2A cRNA
probe (exposure time 10 d; A, C, E, G) or incubated with
[125I]DOI (exposure time 3 d; B, D, F,
H). Sections are from adult control sham-operated rats (A,
B), adult rats injected with 6-OHDA as neonates (C, D),
and from adult rats injected with 6-OHDA as neonates and treated
chronically with apomorphine (E, F) or SKF-38393 (G,
H). The labeling intensity in each condition was measured by
computerized densitometry in the four striatal sectors illustrated in
Figure 1B. The surface of analysis shown for the dorsomedial
sector was identical for the three other striatal sectors.
[View Larger Version of this Image (114K GIF file)]
Observation of the emulsion radioautographs revealed the presence of
neurons intensely labeled with the dark-blue alkaline-phosphatase
reaction product in the striatum. In contrast, no such labeling could
be detected in the overlying cerebral cortex (not shown). In many
instances, the digoxigenin-unlabeled neuronal profiles could be
distinguished from the surrounding neuropil as light blue spots (see
Fig. 5). In addition, the presence of silver grains accumulations on
digoxigenin-unlabeled neurons allowed their unambiguous identification.
Neuronal profiles showing an accumulation of three or more silver
grains were considered labeled with the 5-HT2A
cRNA probe.
Fig. 5.
Bright-field photomicrographs of brain sections
processed for in situ hybridization histochemistry with a
35S-labeled 5-HT2A cRNA
probe and a digoxigenin-labeled PPE cRNA probe in a ventrolateral
striatal sector. Labeling is from an adult control sham-operated rat
(A), an adult rat lesioned with 6-OHDA as neonate
(B), and an adult rat lesioned with 6-OHDA as neonate and
chronically injected with apomorphine (C) or SKF-38393
(D). Neurons labeled with the 5-HT2A
cRNA probe are indicated by the arrows. Note the increased
labeling on the PPE-unlabeled neuron of the 6-OHDA-lesioned rat
(B). Scale bar, 10 µm.
[View Larger Version of this Image (80K GIF file)]
Labeling with the 5-HT2A cRNA probe was visible
in digoxigenin-labeled as well as in digoxigenin-unlabeled neurons.
Comparison with adjacent Nissl-stained sections indicated that almost
90% of the striatal neurons in the medial and ~70% of the striatal
neurons in the lateral sector were labeled with the
5-HT2A cRNA probe (Table 1). The
average numbers of neurons labeled with the
5-HT2A cRNA probe (PPE-labeled and PPE-unlabeled)
were slightly lower but not significantly different in the lateral than
in the medial striatal sector (Table 1). A large majority (over 95%)
of PPE-labeled neurons exhibited 5-HT2A labeling
in the lateral and medial striatal sectors. In both striatal sectors, a
proportion of 50-60% of neurons expressing the
5-HT2A mRNA was also labeled with the PPE cRNA
probe. As estimated from one representative control rat, the level of
labeling with the 5-HT2A cRNA probe was higher in
neurons of the ventromedial than in neurons of the ventrolateral
striatal sector in both PPE-unlabeled (+48%; 100.2 ± 7.7 vs 67.9 ± 4.2 pixels per neuron; n = 50) and PPE-labeled (+35%; 107.6 ± 8.4 vs 79.7 ± 7.2 pixels per neuron; n = 50)
neurons.
Table 1.
Average numbers (per 0.212 mm2 of tissue
section) of neurons labeled with the 5-HT2A cRNA,
double-labeled with the 5-HT2A and PPE cRNAs, or
Nissl-stained on adjacent sections in two sectors of the
striatum
|
5HT2A
(n)
|
5HT2A+PPE
(n)
|
Nissl
|
| Medial |
Lateral |
Medial |
Lateral |
Medial |
Lateral |
|
| Control |
129 ± 12 |
110 ± 10 |
66 ± 5 |
61 ± 5 |
146 ± 10 |
151 ± 10 |
| Lesioned |
160 ± 9 |
156 ± 7* |
81 ± 6 |
83 ± 3* |
152 ± 10 |
170 ± 7 |
| Apomorphine |
139 ± 8 |
105 ± 10 |
91 ± 4 |
69 ± 5 |
134 ± 12 |
133 ± 19 |
| SKF-38393 |
139 ± 17 |
119 ± 9 |
80 ± 8 |
75 ± 7 |
151 ± 10 |
143 ± 2 |
|
|
Average numbers of neurons sampled in a microscopic field
corresponding to an area of 0.212 mm2. The total number of
neurons labeled with the 5-HT2A cRNA probe
(5-HT2A), double-labeled with the 5-HT2A and
the PPE cRNA probes (5-HT2A+PPE), or Nissl-stained on
adjacent sections was calculated in two sectors, medial and lateral, of
the striatum. Data are from adult control sham-operated rats (control),
rats that received 6-OHDA as neonates (lesioned), and rats that
received 6-OHDA as neonates and were treated with apomorphine or
SKF-38393 as adults. The values are means (±SEM) from six rats per
condition. ANOVAs indicated significant differences between
experimental groups for the lateral striatal sector only (see Results).
*, Significantly different from the controls or from the apomorphine-
and SKF-38393-treated rats with the Fisher's test.
|
|
Effect of neonatal 6-OHDA injections and administration of
dopamine-receptor agonists on 5-HT2A mRNA levels
Brain sections from adult, sham-operated or 6-OHDA-lesioned, rats
were first processed for [3H]mazindol binding
to evaluate the loss of dopamine axon terminals in the striatum after
neonatal 6-OHDA injections. Intense
[3H]mazindol labeling was observed in the
striatum of sham-operated rats (Fig. 2A). In
contrast, very weak labeling was observed in the striatum of rats
injected with 6-OHDA as neonates and treated or not with apomorphine or
SKF-38393 as adults (Figs. 2B, 3). In
accordance with a previous report (Molina-Holgado et al., 1994 ), the
levels of [3H]citalopram binding to 5-HT
reuptake sites were significantly increased in the striatum of rats
injected with 6-OHDA as neonates (Fig. 2C,D). Chronic
administration of apomorphine or SKF-38393 to these rats did not affect
the levels of [3H]citalopram binding that
remained significantly higher than the levels measured in sham-operated
rats (Fig. 3).
Fig. 2.
Negative images of x-ray films from frontal
brain sections processed for [3H]mazindol
(exposure time 3 weeks; A, B) or
[3H]citalopram (exposure time 4 weeks; C,
D) binding. Sections are from adult control sham-operated rats
(A, C) or adult rats injected with 6-OHDA as neonates
(B, D).
[View Larger Version of this Image (117K GIF file)]
Fig. 3.
Level of [3H]mazindol or
[3H]citalopram binding in the striatum of adult
control sham-operated rats (control), adult rats lesioned with 6-OHDA
as neonates (lesioned), and adult rats injected with 6-OHDA as neonates
and chronically injected with apomorphine, SKF-38393, or a combination
of SKF-38393 and SCH-23390. Labeling was measured by computerized
densitometry on x-ray film radioautographs. The values represent the
average labeling from six rats in each experimental group and are
expressed as a percentage of the controls. ANOVAs for
[3H]mazindol or
[3H]citalopram binding indicated statistical
significant differences between experimental groups
(F(4,24) = 4.5, p < 0.0001 and
F(4,24) = 3.1, p < 0.05, respectively). *p < 0.05, **p < 0.005 when
compared to controls with the Fisher's test.
[View Larger Version of this Image (35K GIF file)]
The quantification of labeling with the 5-HT2A
cRNA probe was performed on x-ray film radioautographs at two frontal
levels of the striatum; that is, A = 10 and A = 9.2, according to the
stereotaxic atlas of Paxinos and Watson (1986) . At the rostral-most
level (A = 10.0), the ANOVAs demonstrated significant differences in
5-HT2A mRNA levels between the five experimental
groups of rats in the dorsomedial (F(4,23) = 7.4; p = 0.0006), the ventromedial
(F(4,23) = 6.6; p = 0.0011), the
dorsolateral (F(4,23) = 5.8, p = 0.0022), and the ventrolateral (F(4,23) = 5.9, p = 0.0021) striatal sectors. At the caudal-most level (A = 9.2), the ANOVAs demonstrated significant differences in
5-HT2A mRNA levels between the five experimental
groups in the dorsomedial (F(4,25) = 8.6, p = 0.0002), the dorsolateral
(F(4,25) = 8.5, p = 0.0002), the
ventrolateral (F(4,25) = 9.0, p = 0.0001) but not the ventromedial striatal sector.
At the rostral-most level of the striatum, the average level of
labeling with the 5-HT2A cRNA probe was
significantly increased in the four striatal sectors of 6-OHDA-lesioned
rats when compared to the labeling in sham-operated rats (Fig.
4A). The increased labeling was more
prominent in the lateral than in the medial striatal sectors (Fig.
4A). At the caudal-most level of the striatum, the average
5-HT2A mRNA labeling was increased in the
dorsolateral, the ventrolateral, and the dorsomedial sectors of
6-OHDA-lesioned rats (Fig. 4B). At the two frontal levels
examined, the labeling with the 5-HT2A cRNA probe
in 6-OHDA-lesioned rats appeared homogeneously distributed over the
whole striatal surface (Fig. 1C). Chronic apomorphine or
SKF-38393 administration to adult rats lesioned with 6-OHDA as neonates
abolished the increases in 5-HT2A mRNA levels in
all, except the ventromedial, striatal sectors (Figs.
1C,E,G, 4A,B). As a consequence, the striatum of
rats lesioned with 6-OHDA as neonates and treated with apomorphine or
SKF-38393 exhibited a pronounced latero-medial gradient of labeling
with the 5-HT2A cRNA probe that resembled the
gradient observed in sham-operated rats (Fig. 1E,G). The
effects of SKF-38393 on 5-HT2A mRNA levels were
blocked by concomitant administration of the dopamine D1 receptor
antagonist SCH-23390 (Figs. 4A,B).
Fig. 4.
Levels of 5-HT2A mRNA
(A, B) or [125I]DOI binding
(C) in the striatum of adult control sham-operated rats
(control), adult rats lesioned with 6-OHDA as neonates (lesioned), and
adult rats injected with 6-OHDA as neonates and chronically injected
with apomorphine, SKF-38393, or a combination of SKF-38393 and
SCH-23390. The values represent the average intensity of labeling
measured on x-ray films by computerized densitometry and expressed as a
percentage of the controls at frontal levels A = 10 or A = 9.2 according to the stereotaxic atlas of Paxinos and Watson (1986) . The
data (mean ± SEM) were obtained from six rats in each group. Labeling
was measured in four different striatal sectors (DM,
dorsomedial; VM, ventromedial; DL, dorsolateral;
and VL, ventrolateral). Statistical differences in labeling
in each striatal sector were determined after a one-way ANOVA. Pairwise
comparisons between different experimental conditions were made
according to the Fisher's test. *, p < 0.01, **,
p < 0.005 when compared to the controls; #, p < 0.01, or ##, p < 0.005 when compared to the
6-OHDA-lesioned; and ¶, p < 0.01, or ¶¶, p < 0.005 when compared to the SKF-38393-treated rats.
[View Larger Version of this Image (35K GIF file)]
Effects of neonatal 6-OHDA injections and administration of
dopamine receptor agonists on [125I]DOI binding
levels
[125I]DOI binding levels were measured on
x-ray film radioautographs at only one frontal level of the striatum (A = 9.2). The ANOVAs performed for each striatal sector revealed highly
significant differences in [125I]DOI binding
levels between experimental groups in the dorsomedial
(F(4,21) = 5.2, p = 0.0047), the
dorsolateral (F(4,21) = 10.8, p < 0.0001), and the ventrolateral (F(4,21) = 9.2, p = 0.002) but not the ventromedial
(F(4,21) = 2.8, p = 0.0507) striatal
sector.
When compared to sham-operated rats, [125I]DOI
binding levels in 6-OHDA-lesioned rats were significantly increased in
the dorsolateral and the ventrolateral striatal sectors only (Figs.
1D 4C). In the medial striatal sectors, there
were small increases in labeling that did not reach statistical
significance (Fig. 4C). As a result of the preferential
increase in the lateral striatal sectors,
[125I]DOI labeling in 6-OHDA-lesioned rats
appeared homogeneously distributed over the whole striatal surface
(Fig. 1D). Chronic administration of apomorphine or
SKF-38393 to 6-OHDA-lesioned rats abolished the increases in
[125I]DOI binding levels in the dorsolateral
and ventrolateral striatal sectors but did not produce any
statistically significant effect in the dorsomedial or ventromedial
striatal sectors (Figs. 1D,F,H, 4C). The
selective effect of apomorphine and SKF-38393 in the lateral striatal
sectors resulted in a pronounced latero-medial gradient of distribution
of [125I]DOI labeling that resembled the
distribution observed in sham-operated rats (Fig. 1F,H). The
effects of SKF-38393 on striatal [125I]DOI
levels were antagonized by the concomitant administration of SCH-23390
(Fig. 4C).
Cellular distribution of the mRNA encoding for the
5-HT2A receptor
Analysis of the emulsion radioautographs indicated that, as in
control rats, the 5-HT2A mRNA labeling in
6-OHDA-lesioned rats was distributed in PPE-labeled as well as in
PPE-unlabeled neurons (Table 1). In addition, more than 95% of
PPE-labeled neurons also expressed the 5-HT2A
mRNA. In each experimental group, the numbers of neurons exclusively
labeled with the radioactive 5-HT2A cRNA probe or
double-labeled with the 5-HT2A and the PPE cRNA
probes were not significantly different in the lateral and medial
striatal sectors (Table 1). In addition, the numbers of single- or
double-labeled neurons in the medial striatum were not significantly
different between experimental groups (Table 1). In the lateral
striatal sector, however, the ANOVAs indicated a significant difference
between experimental groups in the number of neurons expressing the
5-HT2A mRNA (F(4,23) = 3.5; p = 0.0231) or expressing both the
5-HT2A and the PPE mRNAs
(F(4,23) = 4.6; p = 0.0073).
Therefore, the numbers of neurons (labeled or not with the PPE cRNA
probe) expressing the 5-HT2A mRNA were slightly
higher in 6-OHDA-lesioned rats when compared to the sham-operated rats
or when compared to the 6-OHDA-lesioned rats that were treated with
apomorphine or SKF-38393 (Table 1). In contrast, the numbers of
Nissl-stained neuronal profiles in all these groups were not
significantly different (Table 1). This indicated that some striatal
neurons in the lateral sector of control and 6-OHDA-lesioned rats
treated with apomorphine or SKF-38393 did not express the
5-HT2A mRNA or were below the threshold of
detection.
Quantification of 5-HT2A mRNA levels was
then performed on emulsion radioautographs in individual neurons
labeled or unlabeled with PPE in a ventrolateral striatal sector (Fig.
5). The ANOVAs indicated significant differences between
experimental groups in the number of pixels per neuron in PPE-unlabeled
(F(4,20) = 6.4, p = 0.0018) but not
PPE-labeled (F(4,20) = 0.406, p = 0.8020) striatal neurons (Fig. 6). Pairwise comparisons
with sham-operated rats showed that the 5-HT2A
mRNA labeling in 6-OHDA-lesioned rats was significantly increased in
PPE-unlabeled neurons (Figs. 5A,B, 6). This increase was
abolished after apomorphine or SKF-38393 administration (Figs.
5B-D, 6). The effect of SKF-38393 on
5-HT2A mRNA labeling in PPE-unlabeled neurons was
blocked by concomitant administration of SCH-23390 (Fig. 6). The
histograms of frequency distribution of the
5-HT2A mRNA labeling in PPE-labeled and
PPE-unlabeled neurons shown in Figure 7 illustrate the
increase of 5-HT2A mRNA labeling in the
population of PPE-unlabeled neurons in 6-OHDA-lesioned rats and its
reversal after apomorphine or SKF-38393 administration.
Fig. 6.
Levels of 5-HT2A mRNA
labeling in single PPE-labeled and PPE-unlabeled neurons in a
ventrolateral sector of the striatum. Radioautographic labeling was
measured by computerized image analysis (see Materials and Methods for
details). The values are means ± SEM of the average number of pixels
per neuron and are expressed as a percentage of the controls. Data are
from adult control sham-operated rats (control), rats that received
6-OHDA as neonates (lesioned), and rats that received 6-OHDA as
neonates and were treated with apomorphine, SKF-38393, or a combination
of SKF-38393 and SCH-23390 as adults. A sample of 50 neurons per rat
from six rats per experimental condition was analyzed. Pairwise
comparisons between experimental groups were made with a Fisher's
test. *, p < 0.01 when compared to the controls; #,
p < 0.01 when compared to the lesioned rats; and ¶,
p < 0.01 when compared to the SKF-38393-treated rats.
[View Larger Version of this Image (46K GIF file)]
Fig. 7.
Histograms of frequency distributions of
5-HT2A mRNA labeling in PPE-labeled and
PPE-unlabeled neurons of the lateral striatum. Data are from adult
control sham-operated rats (Control), rats that received
6-OHDA as neonates (Lesioned), and rats that received
6-OHDA as neonates and were treated with apomorphine, SKF-38393 or a
combination of SKF-38393 and SCH-23390 as adults. Quantification of
silver grains over individual striatal neurons was performed by
computerized image analysis (see Materials and Methods for details).
The area covered by silver grains is expressed in number of pixels per
neuron. A sample of 50 neurons per rat from six rats in each
experimental condition was analyzed.
[View Larger Version of this Image (28K GIF file)]
DISCUSSION
Our results indicate that neonatal 6-OHDA lesions induce
concomitant increases in the levels of serotonin
5-HT2A receptor and mRNA in the adult rat
striatum. Such increases are abolished in the lateral sectors of the
striatum after chronic and systemic administration of apomorphine or
SKF-38393. The changes in mRNA levels encoding for the
5-HT2A receptor are restricted to a subpopulation
of striatal neurons that do not express the PPE mRNA.
Distribution of the striatal 5-HT2A receptor and
its mRNA
The distribution of labeling with the 5-HT2A
cRNA probe in the striatum of control rats was similar to the
distribution observed with [125I]DOI. In both
cases, labeling was heterogeneous and was more intense in the medial
sectors of the striatum. This similar distribution of labeling is a
strong indication that the cRNA probe and
[125I]DOI specifically labeled the
5-HT2A mRNA and receptor, respectively. This is
consistent with previous reports showing that DOI in presence of 30 nM 5-HT labels the 5-HT2A
but not the closely related 5-HT2C (formerly
5-HT1C) receptor site (Mengod et al., 1990 ). The
comparable distribution of labeling with the cRNA probe and with
[125I]DOI also suggests that most striatal
5-HT2A receptors are distributed in cell bodies.
This conclusion is consistent with previous reports (Fishette et al.,
1988; Mengod et al., 1990 ; Pompeiano et al., 1994 ). A proportion of
striatal 5-HT2A receptors would also be localized
on dopaminergic nerve terminals (Muramatsu et al., 1988 ). However, this
fraction of receptors was probably not detected in 6-OHDA-lesioned
rats, and the changes in striatal [125I]DOI
binding levels measured in these rats most likely reflect changes in
the number of postsynaptic receptors.
After neonatal 6-OHDA lesions, increased levels of the
5-HT2A receptor and mRNA were particularly
prominent in the lateral striatal sectors. As a consequence, the
heterogeneous distribution of labeling observed in control rats became
rather homogeneous in 6-OHDA-lesioned rats. Chronic administration of
apomorphine or SKF-38393 resulted again in a pronounced latero-medial
gradient of distribution of labeling. Cellular analysis indicated that
this gradient was primarily attributable to higher
5-HT2A mRNA levels in neurons of the medial
striatal sectors. Altogether, these results suggest that the
heterogeneous distribution of the 5-HT2A receptor
in the rat striatum is under the control of dopamine. In particular,
dopamine appears to exert an inhibitory control on the expression of
the 5-HT2A receptor and/or mRNA in neurons of the
lateral striatum.
At the caudal-most level examined, the correspondence between
the levels of 5-HT2A mRNA and
[125I]DOI binding was not observed in the
dorsomedial sector of the striatum. In this sector, increased
5-HT2A mRNA levels in 6-OHDA-lesioned rats were
paralleled by a small but nonsignificant increase in
[125I]DOI binding levels. In addition,
administration of apomorphine or SKF-38393 abolished the increased
levels of the 5-HT2A mRNA, but it had no
consistent effect on [125I]DOI binding levels.
This suggests a certain degree of mismatch between the regulation of
the mRNA and the receptor itself in this dorsomedial striatal
sector.
Regulation of striatal 5-HT receptors by dopamine
receptor agonists
Administration of apomorphine or SKF-38393 had a comparable
inhibitory effect on the levels of the striatal
5-HT2A receptor and its mRNA. Furthermore, the
effect of SKF-38393 was blocked by the preferential dopamine D1
receptor antagonist SCH-23390. These results strongly suggest that the
effects of apomorphine and SKF-38393 are mediated by D1 receptors. In
normal rats, systemic administration of apomorphine has been shown to
induce an increase in the intracellular levels of 5-HT in the raphe
dorsalis and a decrease in the extracellular concentration of 5-HT in
the striatum (Lee and Geyer, 1992; Ferré et al., 1994 ). The
regulation of 5-HT levels by apomorphine is mediated by dopamine D2,
but not D1, receptors in the raphe dorsalis (Ferré and Artigas,
1993 ). In addition, when directly infused into the striatum,
apomorphine or SKF-38393 do not alter the extracellular concentration
of serotonin (Ferré et al., 1994 ). In light of these previous and
our own results, it seems unlikely that the effects of apomorphine or
SKF-38393 on the levels of the 5-HT2A receptor
and its mRNA involve an action on striatal 5-HT neurons. This
interpretation is also supported by the fact that apomorphine or
SKF-38393 failed to alter the increases in citalopram binding levels
measured in 6-OHDA-lesioned rats.
Changes in 5-HT2A mRNA levels in 6-OHDA-lesioned
rats were exclusively observed in the subpopulation of striatal neurons
that do not express the PPE mRNA. It has been previously shown that the
majority of striato-pallidal neurons contain the mRNA encoding for
enkephalin whereas the majority of striato-nigral neurons express the
mRNAs encoding for dynorphin and substance P, but not enkephalin
(Gerfen et al., 1990 ; for review, see also Gerfen, 1992 ). Thus, our
results suggest that the 5-HT2A mRNA is expressed
in both striato-pallidal and striato-nigral neurons but its regulation
by dopamine receptors occurs only in striato-nigral neurons.
Striato-nigral neurons have been shown to preferentially express the
dopamine D1 receptor (Gerfen et al., 1990 ) whereas striato-pallidal
neurons express the D2 receptor (Gerfen et al., 1990 ; Le Moine et al.,
1990). It can thus be speculated that D1 receptors are coupled to
intracellular pathways that directly participate in the regulation of
the 5-HT2A receptor and/or mRNA.
Functional consequences of 5-HT2A
receptor regulation
The increased number of 5-HT2A receptors
after neonatal 6-OHDA injections may result in hypersensitive responses
of striatal neurons to serotonin. This interpretation is supported by
previous findings of increased responsiveness of striatal neurons to
the inhibitory action of 5-HT or DOI (El Mansari et al., 1994 ). Another
study has shown, however, that 5-HT in such rats elicit excitations
rather than inhibitions of striatal neurons (Luthman et al., 1993 ).
Eventual changes in the responsiveness of striatal neurons to
5-HT2A receptor agonists after neonatal 6-OHDA
would be associated with an increase in evoked release of striatal 5-HT
(Jackson and Abercrombie, 1992 ) without concomitant changes in the
extracellular levels or basal release of 5-HT (Jackson and Abercrombie,
1992 ; Luthmann et al., 1993; Molina-Holgado et al., 1993 , 1994 ). After
chronic administration of dopamine receptor agonists to rats lesioned
with 6-OHDA as neonates, it can be expected that the hypersensitivity
of striatal neurons to 5-HT receptor agonists will be reversed or
attenuated as a consequence of decreased expression of the
5-HT2A receptor.
Previous reports have shown that systemic administration of DOI to
adult rats can induce an increase in striatal substance P mRNA and
peptide levels (Walker et al., 1991 ). In addition, lesions of 5-HT
neurons with 5,7-dihydroxytryptamine result in a decrease in dynorphin
levels without concomitant changes in the levels of striatal PPE mRNA
(Morris et al., 1992). On the other hand, a facilitatory role of D1
receptor agonists on the levels of striatal dynorphin and substance P
mRNAs has been documented previously (Gerfen et al., 1990 ). Altogether,
these studies indicate that dopamine through D1 receptors, and 5-HT
through 5-HT2A receptors, exert a facilitatory
control on the expression of peptides in striato-nigral neurons. It is
therefore possible that the control of dopamine D1 receptors on the
expression of serotonin 5-HT2A receptors has
important consequences on the regulation of neurotransmitters in
striato-nigral neurons.
Adult rats injected with 6-OHDA as neonates do not exhibit the severe
behavioral abnormalities observed when similar extensive lesions are
performed on adults (Breese et al., 1984 , Bruno et al., 1987 ;
Weihmuller and Bruno; 1989; Zigmond et al., 1990 ; Johnson and Bruno,
1992 ). However, these rats exhibit some learning deficits as well as a
motor hyperactivity and a behavioral hypersensitivity to the
administration of dopamine D1 agonists (Erinoff et al., 1979 ; Heffner
et Seiden, 1982; Breese et al., 1984 , 1985a ,b; Schallert et al., 1989;
Gong et al., 1992 , 1993 ). The motor hyperactivity can be reversed by
the systemic administration of ketanserin or mianserin and therefore
appears to be mediated by 5-HT2A receptors
(Luthman et al., 1991 ). Altered expression of
5-HT2A receptors in rats lesioned with 6-OHDA as
neonates might thus play a critical role in the genesis and maintenance
of this motor hyperactivity.
Conclusions
The major finding of the present study is that stimulation of
dopamine D1 receptors inhibits the expression of
5-HT2A receptors in presumed striato-nigral
neurons of the lateral striatum. In the rat striatum, the lateral
regions are involved in sensorimotor functions (Dunnett and Iversen,
1981). The control of serotonin 5-HT2A receptors
by D1 receptors in the lateral striatum might thus represent an
important mechanism involved in the regulation of sensorimotor and
motor striatal functions. In keeping with evidence showing that 5-HT
increases the release of dopamine in the striatum (Benloucif et al.,
1993 ; Gallaway et al., 1993; Yadid et al., 1994 ; Bonhomme et al.,
1995 ), the negative control of dopamine receptors on the expression of
5-HT2A receptors can be viewed as a homeostatic
mechanism aimed at balancing the effects of dopamine and 5-HT on motor
activity.
FOOTNOTES
Received Jan. 19, 1996; revised March 6, 1996; accepted March 8, 1996.
The studies were funded by the Parkinson Foundation of Canada, the
Natural Sciences and Engineering Research Council, and the Fonds de
Recherche en Santé du Québec (FRSQ) to J.-J.S., and by the
Medical Research Council of Canada (MT12966) and the FRSQ to T.A.R. We
thank Dr. D. Pritchett for the gift of the 5-HT2A
receptor cDNA and Ms. G. Audet and Ms. I. Deaudelin for their expert
technical assistance.
Correspondence should be addressed to Dr. Jean-Jacques Soghomonian,
Centre de Recherche en Neurobiologie, Hôpital de
l'Enfant-Jésus, 1401 18 Rue, Québec, Canada G1J
1Z4.
REFERENCES
-
Benloucif S,
Keegan MJ,
Galloway MP
(1993)
Serotonin-facilitated dopamine release in
vivo: pharmacological characterization.
J Pharmacol Exp Ther
265:373-377 .
[Abstract/Free Full Text]
-
Berger TW,
Kaul S,
Stricker EM,
Zigmond MJ
(1985)
Hyperinnervation of the striatum by dorsal raphe
afferents after dopamine-depleting brain lesions in neonatal rats.
Brain Res
336:354-358 .
[ISI][Medline]
-
Bonhomme N,
De Deurwaèrdere P,
Le Moal M,
Spampinato U
(1995)
Evidence for 5-HT4 receptor
subtype involvement in the enhancement of striatal dopamine release
induced by serotonin: a microdialysis study in the
halothane-anesthetized rat.
Neuropharmacology
34:269-279 .
[ISI][Medline]
-
Breese GR,
Baumeister AA,
McCown TJ,
Emerick SG,
Frye GD,
Crotty K,
Mueller RA
(1984)
Behavioral differences between neonatal and
adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to
neurological symptoms in clinical syndromes with reduced brain
dopamine.
J Pharmacol Exp Ther
231:343-354 .
[Abstract/Free Full Text]
-
Breese GR,
Baumeister AA,
Napier TC,
Frye GD,
Mueller RA
(1985a)
Evidence that D1 dopamine receptors contribute to
the supersensitive behavioral responses induced by
l-dihydroxyphenylalanine in rats treated neonatally with
6-hydroxydopamine.
J Pharmacol Exp Ther
235:287-294 .
[Abstract/Free Full Text]
-
Breese GR,
Napier TC,
Mueller RA
(1985b)
Dopamine
agonist-induced locomotor activity in rats treated with
6-hydroxydopamine at differing ages: functional supersensitivity of D1
dopamine receptors in neonatally lesioned rats.
J Pharmacol Exp Ther
234:447-455 .
[Abstract/Free Full Text]
-
Bruno JP,
Jackson D,
Zigmond MJ,
Stricker EM
(1987)
Effect of
dopamine-depleting brain lesions in rat pups: role of striatal
serotonergic neurons in behavior.
Behav Neurosci
101:806-811 .
[ISI][Medline]
-
Cox KH,
DeLeon DV,
Angerer LM,
Angerer RC
(1984)
Detection of
mRNAs in sea urchin embryos by in situ hybridization using
asymmetric RNA probes.
Dev Biol
101:485-502 .
[ISI][Medline]
-
Descarries L,
Soghomonian J-J,
Garcia S,
Doucet G,
Bruno JP
(1992)
Ultrastructural analysis of the serotonin
hyperinnervation in adult rat neostriatum following neonatal dopamine
denervation with 6-hydroxydopamine.
Brain Res
569:1-13 .
[ISI][Medline]
-
Dunnett SB,
Iversen SD
(1982)
Sensorimotor impairments
following localized kainic acid and 6-hydroxydopamine lesions of the
neostriatum.
Brain Res
248:121-127 .
[ISI][Medline]
-
El Mansari M,
Radja F,
Ferron A,
Reader T,
Molina-Holgado E,
Descarries L
(1994)
Hypersensitivity to serotonin and its agonists in
serotonin-hyperinnervated neostriatum after neonatal dopamine
denervation.
Eur J Pharmacol
261:171-178 .
[ISI][Medline]
-
Erinoff L,
MacPhail RC,
Heller A,
Seiden LS
(1979)
Age-dependent effects of 6-hydroxydopamine on
locomotor activity in the rat.
Brain Res
164:195-199 .
[ISI][Medline]
-
Ferré S,
Artigas F
(1993)
Dopamine D2 receptor-mediated
regulation of serotonin extracellular concentration in the dorsal raphe
nucleus of freely moving rats.
J Neurochem
61:772-776 .
[ISI][Medline]
-
Ferré S,
Cortés R,
Artigas F
(1994)
Dopaminergic
regulation of the serotonergic raphe-striatal pathway: microdialysis
studies in freely moving rats.
J Neurosci
14:4839-4846 .
[Abstract]
-
Fischette CT,
Nock B,
Renner K
(1987)
Effects of
5,7-dihydroxytryptamine on serotonin1 and serotonin2 receptors
throughout the rat central nervous system using quantitative
autoradiography.
Brain Res
421:263-279 .
[ISI][Medline]
-
Galloway MP,
Suchowski CS,
Keegan MJ,
Hjorth S
(1993)
Local
infusion of the selective 5-HT-1b agonist CP-93,129 facilitates
striatal dopamine release in vivo.
Synapse
15:90-92 .
[ISI][Medline]
-
Gerfen CR
(1992)
The neostriatal mosaic: multiple levels of
compartmental organization in the basal ganglia.
Annu Rev Neurosci
15:285-320 .
[ISI][Medline]
-
Gerfen CR,
Engber TM,
Mahan LC,
Susel Z,
Chase TN,
Monsma FJ,
Sibley DR
(1990)
D1 and D2 dopamine receptor-regulated gene
expression of striatonigral and striatopallidal neurons.
Science
250:1429-1432 .
[Abstract/Free Full Text]
-
Gong L,
Kostrzewa RM,
Fuller RW,
Perry KW
(1992)
Supersensitization of the oral response to
SKF-38393 in neonatal 6-OHDA-lesioned rats is mediated through a
serotonin system.
J Pharmacol Exp Ther
261:1000-1007 .
[Abstract/Free Full Text]
-
Gong L,
Kostrzema RM,
Perry KW,
Fuller RW
(1993)
Dose-related
effects of a neonatal 6-OHDA lesion on SKF-38393- and
µ-chlorophenylpiperazine-induced oral activity responses of rats.
Dev Brain Res
76:233-238 .
[Medline]
-
Heffner TG,
Seiden LS
(1982)
Possible involvement of
serotonergic neurons in the reduction of locomotor hyperactivity caused
by amphetamine in neonatal rats depleted of brain dopamine.
Brain Res
244:81-85 .
[ISI][Medline]
-
Jackson D,
Abercrombie ED
(1992)
In vivo
neurochemical evaluation of striatal serotonergic hyperinnervation in
rats depleted of dopamine at infancy.
J Neurochem
58:890-897 .
[ISI][Medline]
-
Javitch JA,
Strittmatter SM,
Snyder SH
(1985)
Differential
visualization of dopamine and norepinephrine uptake sites in rat brain
using [3H]mazindol autoradiography.
J Neurosci
5:1513-1521 .
[Abstract]
-
Johnson BJ,
Bruno JP
(1992)
D1 and D2 receptor mediation of
sensorimotor behavior in rats depleted of dopamine during development.
Behav Brain Res
47:49-53 .
[ISI][Medline]
-
Kelland MD,
Freeman AS,
Chiodo LA
(1990)
Serotonergic
afferent regulation of the basic physiology and pharmacological
responsiveness of nigrostriatal dopamine neurons.
J Pharmacol Exp Ther
253:803-811 .
[Abstract/Free Full Text]
-
Lee EH,
Geyer MA
(1984)
Indirect effects of apomorphine on
serotoninergic neurons in rats.
Neuroscience
11:437-442 .
[ISI][Medline]
-
LeMoine C,
Normand E,
Guitteny AF,
Fouque B,
Teoule R,
Bloch B
(1990)
Dopamine receptor gene expression by enkephalin
neurons in rat forebrain.
Proc Natl Acad Sci USA
87:230-234.
[Abstract/Free Full Text]
-
Luthman J,
Bolioli B,
Tsutsumi T,
Verhofstad A,
Jonsson G
(1987)
Sprouting of striatal serotonin nerve terminals
following selective lesions of nigro-striatal dopamine neurons in
neonatal rat.
Brain Res Bull
19:269-274 .
[ISI][Medline]
-
Luthman JA,
Fredriksson A,
Plaznik A,
Archer T
(1991)
Ketanserin and mianserin treatment reverses
hyperactivity in neonatally dopamine-lesioned rats.
J Psychopharmacol
5:418-422.
-
Luthman J,
Friedmann M,
Bickford P,
Olson L,
Hoffer BJ,
Gerhardt GA
(1993)
In vivo electrochemical measurements and
electrophysiological studies of rat striatum following neonatal
6-hydroxydopamine treatment.
Neuroscience
52:677-687 .
[ISI][Medline]
-
McKenna DJ,
Nazarali AJ,
Hoffman AJ,
Nichols DE,
Mathis CA,
Saavedra JM
(1989)
Common receptors for hallucinogens in rat brain: a
comparative autoradiographic study using
[125I]LSD and
[125I]DOI, a new psychomimetic radioligand.
Brain Res
476:45-56 .
[ISI][Medline]
-
Mengod G,
Pompeiano M,
Martinez-Mir I,
Palacios JM
(1990)
Localization of the mRNA for
5-HT2 receptor by in situ
hybridization histochemistry: correlation with the distribution of
receptor site.
Brain Res
524:139-143 .
[ISI][Medline]
-
Molina-Holgado E,
Dewar KM,
Grondin L,
van Gelder NM,
Reader TA
(1993)
Changes of amino acid and monoamine levels after
neonatal 6-hydroxydopamine denervation in rat basal ganglia, substantia
nigra, and raphe nuclei.
J Neurosci Res
35:409-418 .
[ISI][Medline]
-
Molina-Holgado E,
Dewar KM,
Descarries L,
Reader TA
(1994)
Altered dopamine and serotonin metabolism in the
dopamine-denervated and serotonin-hyperinnervated neostriatum of adult
rat after neonatal 6-hydroxydopamine.
J Neurosci Res
35:409-418 .
-
Morris BJ,
Reimer S,
Hollt V,
Herz A
(1988)
Regulation of
striatal prodynorphin mRNA levels by the raphe-striatal pathway.
Brain Res
464:15-22 .
[Medline]
-
Muramatsu M,
Tamaki-Ohashi J,
Usuki C,
Araki H,
Chaki S,
Aihara H
(1988)
5-HT2 antagonists and minaprine block the
5-HT-induced inhibition of dopamine release from rat brain striatal
slices.
Eur J Pharmacol
153:89-95 .
[ISI][Medline]
-
Numan S,
Lundgren KH,
Wright DE,
Herman JP,
Seroogy KB
(1995)
Increased expression of 5HT2 receptor mRNA in rat
striatum following 6-OHDA lesions of the adult nigrostriatal pathway.
Mol Brain Res
29:391-396 .
[Medline]
-
Paxinos G,
Watson C
(1986)
The rat brain in stereotaxic
coordinates, 2nd Ed.
.
-
Pompeiano M,
Mengod G,
Palacios JM
(1994)
Distribution of the
serotonin 5-HT2 receptor family mRNA: comparison
between 5-HT2A and 5-HT2C
receptors.
Brain Res
23:163-178.
-
Pritchett DB,
Bach AWJ,
Wozny M,
Taleb O,
Dal Toso R,
Shih JC,
Seeburg PH
(1988)
Structure and functional expression of cloned rat
serotonin 5HT-2 receptor.
EMBO J
7:4135-4140 .
[ISI][Medline]
-
Radja F,
Descarries L,
Dewar K,
Reader T
(1993)
Serotonin
5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction
of nigrostriatal dopamine neurons: a quantitative autoradiographic
study.
Brain Res
606:273-285 .
[ISI][Medline]
-
Sandyk R
(1988)
Serotonin in involuntary movement disorders.
Int J Neurosci
42:185-205 .
[ISI][Medline]
-
Shallert T,
Petrie BF,
Whishaw IQ
(1989)
Neonatal dopamine
depletion: spared and unspared sensorimotor and attentional disorders
and effects of further depletion in adulthood.
Psychobiology
17:386-396.
-
Snyder AM,
Zigmond MJ,
Lund RD
(1986)
Sprouting of
serotoninergic afferents onto striatum after dopamine-depleting lesions
in infant rats: a retrograde transport and immunocytochemical study.
J Comp Neurol
245:274-281 .
[ISI][Medline]
-
Stackowiak MK,
Bruno JP,
Snyder AM,
Stricker EM,
Zigmond MJ
(1984)
Apparent sprouting of striatal serotonergic
terminals after dopamine-depleting brain lesions in neonatal rats.
Brain Res
291:164-167.
[ISI][Medline]
-
Walker PD,
Riley LA,
Hart RP,
Jonakait GM
(1991)
Serotonin
regulation of tachykinin biosynthesis in the rat neostriatum.
Brain Res
546:33-39 .
[ISI][Medline]
-
Yadid G,
Pacak K,
Kopin IJ,
Goldstein DS
(1994)
Endogenous
serotonin stimulates striatal dopamine release in conscious rats.
J Pharmacol Exp Ther
270:1158-1165 .
[Abstract/Free Full Text]
-
Yoshikawa K,
Williams C,
Sabol SL
(1984)
Rat brain
preproenkephalin mRNA.
J Biol Chem
259:14301-14308 .
[Abstract/Free Full Text]
-
Weihmuller FB,
Bruno JP
(1989)
Age-dependent
plasticity in the dopaminergic control of sensorimotor development.
Behav Brain Res
35:95-109 .
[ISI][Medline]
-
Zigmond MJ,
Abercrombie ED,
Berger TW,
Grace AA,
Stricker EM
(1990)
Compensations after lesions of central dopaminergic
neurons: some clinical and basic implications.
Trends Neurosci
13:290-296 .
[ISI][Medline]
This article has been cited by other articles:

|
 |

|
 |
 
C. Bishop, J. L. Tessmer, T. Ullrich, K. C. Rice, and P. D. Walker
Serotonin 5-HT2A Receptors Underlie Increased Motor Behaviors Induced in Dopamine-Depleted Rats by Intrastriatal 5-HT2A/2C Agonism
J. Pharmacol. Exp. Ther.,
August 1, 2004;
310(2):
687 - 694.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|